Lower levels of ER stress in tunicamycin-treated CHOP^-/- cells. (A) Immunoblots of BiP and eIF2α (a loading control) from wild-type and CHOP^-/- cells treated with varying doses of tunicamycin for 6 h. (B) Immunoblots as in A of cells treated with 0.5μg/mL tunicamycin for the indicated period of time (top two panels) and autoradiograph of immunoprecipitated newly synthesized [³⁵S]BiP following pulse labeling of the treated cells (bottom). (C) Autoradiograph of ³⁵S-labeled Hsp47 immunoprecipitated from wild-type and CHOP^-/- cells briefly pulsed with [³⁵S]methionine after 1 h of exposure to the indicated concentration of tunicamycin. The position of the glycosylated (G) and nonglycosylated (O) forms of Hsp47 on the SDS-PAGE are indicated. Also indicated is an irrelevant band immunoprecipitated by the anti-Hsp47 antiserum (^★) (D) Ethidium bromide-stained gel of unspliced and IRE1-spliced XBP-1 RT-PCR product (reporting on mRNA) following a time course of tunicamycin treatment (0.5 μg/mL). The ratio of spliced/unspliced RNA in each sample in the two genotypes is also presented graphically.

Enhanced recovery of client protein synthesis predis-poses wild-type cells to accumulation of a high-molecular-weight ER protein complex during ER stress. (A) Autoradiograph and Coomassie stain of gel of radiolabeled microsomal proteins isolated by flotation through sucrose from [³⁵S]methionine pulse-labeled wild-type and CHOP^-/- MEFs treated with 400 nM thapsigargin. (B) Autoradiograph (top) and Grp94, BiP, and PDI immunoblots (bottom) of proteins from the wild-type 6-h time point of A following velocity gradient centrifugation through a 10%-40% glycerol gradient. (C) BiP immunoblot from untreated and tunicamycin-treated (2μg/mL, 8 h) wild-type cells. A total of 5% of the input, post-nuclear supernatant (PNS), or the pellet obtained from that post-nuclear supernatant treated with the indicated concentration of SDS and subjected to glycerol gradient centrifugation were loaded in each lane. (D) Immunoblot of BiP from fractions taken through the glycerol gradient from a 0.8% SDS-treated sample as in C (note that BiP migrating through the cushion as a large complex forms a distinct peak that is separated by a clear zone from the low-molecular-weight material). (E) Immunoblot of pelleted BiP (as in D) and 5% of the input post-nuclear supernatant (PNS) BiP from untreated and tunicamycin treated wild-type, CHOP^-/- and GADD34 mutant cells.

Loss of GADD34 phosphatase activity protects the renal epithelium from tunicamycin. (A) Photomicrograhs (10×) of wild-type, GADD34^ΔC/ΔC and CHOP^-/- mouse kidneys stained with hematoxylin and eosin 96 h after injection with 1 μg/gram of tunicamycin. (B) Photomicrographs (100× and 400×) from the same sections. Note the extensive tubular-interstitial damage at the cortico-meduallary junction in the representative wild-type sample and its absence in the mutants. (C) Quantification of tubularinterstitial damage at 96 h in tunicamycin-treated wild-type (n = 12 animals), GADD34^ΔC/ΔC (n = 12), CHOP^+/- (n = 8), and CHOP^-/- (n = 8). Grading by modified Shih scale (Shih et al. 1988) and P values calculated by a Mann-Whitney nonparametric test. (D) Quantification of cell death by counting TUNEL-positive cells per high-powered field (hpf) in kidneys from 12 wild-type and 12 GADD34^ΔC/ΔC animals. The means of two fields per kidney of each animal are presented. The mean ± SEM of each genotype is indicated by a horizontal bar and P values were calculated by 2-tail Student's t-test. (E) Photomicrograph (400×) of cortico-medullary junction of wild-type and GADD34^ΔC/ΔC kidneys stained for TUNEL and counter-stained with Hoescht.

Transcriptional profiling reveals a slowed induction of the UPR and specific gene defects in CHOP^-/- fibroblasts. (A) Graphic representation of the average expression (n = 4) level of 12,488 genes in untreated and tunicamycin-treated, wild-type and CHOP^-/- MEFs. Each vertical bar represents a single gene. Green coloration indicates relatively low levels of expression, and red indicates a relatively high level of expression of a given mRNA. (B) Expansion of the cluster of 206 genes significantly activated by tunicamycin in either wild-type or CHOP^-/- cells. The genes are arranged (left to right) by descending order of inducibility by tunicamycin in the wild-type sample at the 8-h time point.

Impaired induction of GADD34 in CHOP^-/- cells leads to persistent eIF2α phosphorylation during stress. (A) Immunoblot of GADD34, phosphorylated eIF2α (P-eIF2α), total eIF2α (T-eIF2α) ATF4, and CHOP from lysates of tunicamycin-treated wild-type and CHOP^-/- cells. (B) Immunoblot of GADD34 and PDI (a loading control) from lysates of wild-type and CHOP^-/- cells, exposed to 2 μg/mL tunicamycin, 400 nM thapsigargin, 25 μM arsenite, or untreated (UT). (C) Chromatin immunoprecipitation of GADD34 with anti-CHOP antiserum from untreated and tunicamycin-treated (2 μg/mL, 8 h) wild-type and CHOP^-/- cells detected by a quantitative genomic PCR targeting the promoter region or exon 2 of GADD34. The signal in the untreated CHOP^-/- cells was arbitrarily assigned a value of 1.

CHOP-dependent ERO1α induction favors abnormal oxidized protein complexes. (A) Abundance of ERO1α mRNA in untreated and tunicamycin-treated (2 μg/mL, 8 h) wild-type and CHOP^-/- cells measured by quantitative real-time PCR and expressed as the ratio of ERO1α mRNA to β Actin mRNA. (B) Chromatin immunoprecipitation of ERO1α with anti-CHOP antiserum from untreated and tunicamycin-treated wild-type and CHOP^-/- cells detected by a quantitative genomic PCR targeting the promoter region of ERO1α. The signal in the untreated CHOP^-/- cells was arbitrarily assigned a value of 1. (C) Immunoblot of PDI from untreated and tunicamycin-treated wild-type and CHOP^-/- cells challenged in vivo with DTT and then chased in the absence of reducing agent for the indicated period of time before lysis in a nonreducing buffer. Identical samples were loaded on a reducing and nonreducing gel. The position of the low-mobility reduced form (RED) and higher-mobility oxidized form (OX) of PDI is indicated next to the nonreducing SDS-PAGE. An uncharacterized invariant band reactive with the PDI antibody is indicated by the asterisk. (D) Immunoblot of Hsp47 and BiP in SDS-resistant HMW complexes (PELLET) and 5% input post-nuclear supernatant (PNS) from wild-type and CHOP^-/- cells treated with tunicamycin (2 μg/mL) for the indicated time. Identical samples were loaded on a reducing (left) and nonreducing (right) SDS-PAGE. The position of the Hsp47 disulfide-stabilized complex, glycosylated (G) and nonglycosylated (O) monomer and BiP are indicated. (E) Immunoblot of BiP in HMW complex pellet (P) and supernatant (S) from untreated and tunicamycin-treated (2 μg/mL, 8 h) wild-type cells isolated by velocity centrifugation through 20% glycerol cushions containing 100 mM DTT. (F) Immunoblot of BiP and Hsp 47 in SDS-resistant HMW complex (PELLET) and 5% input post-nuclear supernatant (PNS) from wild-type cells treated with tunicamycin (2 μg/mL) and the indicated concentrations of DTT in vivo for 8 h.

Knock-down of ero-1 in C. elegans is protective against the lethal effects of tunicamycin. Survival curves of young adult nematodes raised on mock RNAi, ero-1 RNAi, and sel-1 RNAi, and treated at day 0 with 30 μg/mL of tunicamycin for 24 h.(A) Comparison of the mock RNAi and the ero-1 RNAi. Shown is a representative experiment (n = 3). (B) Comparison of mock RNAi and sel-1 RNAi. The data in A and B are from the same experiment and are represented in two graphs for clarity. P values for the divergence of the curves were determined using two-factor ANOVA analysis. (C) Immunoblot of lysates from hsp-4::gfp animals after growth on the indicated RNAi and treatment for 24 h with 30 μg/mL of tunicamycin. The GFP signal reflects activity of the UPR reporter, while the anti-HDEL antibody detects an invariant 50-kDa band used here as a loading control.